##gff-version 3 P58012 UniProtKB Chain 1 376 . . . ID=PRO_0000091861;Note=Forkhead box protein L2 P58012 UniProtKB DNA binding 54 148 . . . Note=Fork-head;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00089 P58012 UniProtKB Region 1 53 . . . Note=Disordered;Ontology_term=ECO:0000256;evidence=ECO:0000256|SAM:MobiDB-lite P58012 UniProtKB Region 276 342 . . . Note=Disordered;Ontology_term=ECO:0000256;evidence=ECO:0000256|SAM:MobiDB-lite P58012 UniProtKB Compositional bias 303 339 . . . Note=Pro residues;Ontology_term=ECO:0000256;evidence=ECO:0000256|SAM:MobiDB-lite P58012 UniProtKB Modified residue 33 33 . . . Note=Phosphoserine;Ontology_term=ECO:0007744;evidence=ECO:0007744|PubMed:23186163;Dbxref=PMID:23186163 P58012 UniProtKB Cross-link 25 25 . . . Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) P58012 UniProtKB Natural variant 58 58 . . . ID=VAR_021196;Note=In BPES%3B sporadic%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. S->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 63 63 . . . ID=VAR_062545;Note=In BPES. I->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16454982;Dbxref=dbSNP:rs1315073489,PMID:16454982 P58012 UniProtKB Natural variant 65 65 . . . ID=VAR_046490;Note=In BPES. M->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18642388;Dbxref=dbSNP:rs1559922621,PMID:18642388 P58012 UniProtKB Natural variant 66 66 . . . ID=VAR_021197;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. A->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 69 69 . . . ID=VAR_021198;Note=In BPES%3B sporadic%3B nuclear aggregation%3B normal transactivation activity. E->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=dbSNP:rs387906920,PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 80 80 . . . ID=VAR_046491;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 84 84 . . . ID=VAR_046492;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->N;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 84 84 . . . ID=VAR_016883;Note=In BPES%3B type I. I->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12630957;Dbxref=dbSNP:rs28937884,PMID:12630957 P58012 UniProtKB Natural variant 85 85 . . . ID=VAR_016884;Note=In BPES%3B sporadic. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11468277;Dbxref=PMID:11468277 P58012 UniProtKB Natural variant 90 90 . . . ID=VAR_046493;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. F->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 98 98 . . . ID=VAR_046494;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. W->G;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 98 98 . . . ID=VAR_062546;Note=In BPES. W->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs1057516149,PMID:18484667 P58012 UniProtKB Natural variant 101 101 . . . ID=VAR_046495;Note=In BPES%3B nuclear aggregation%3B impaired transactivation activity. S->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=dbSNP:rs1057516151,PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 102 102 . . . ID=VAR_046496;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 103 103 . . . ID=VAR_046497;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B normal transactivation activity. R->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 104 104 . . . ID=VAR_021199;Note=In BPES%3B diffuse nuclear localization as wild type%3B normal transactivation activity. H->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12938087,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs1057516153,PMID:12938087,PMID:18372316 P58012 UniProtKB Natural variant 105 105 . . . ID=VAR_021200;Note=In BPES%3B type II. N->S P58012 UniProtKB Natural variant 106 106 . . . ID=VAR_016885;Note=In BPES%3B sporadic%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. L->F;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs1057516156,PMID:12529855,PMID:18372316 P58012 UniProtKB Natural variant 106 106 . . . ID=VAR_046498;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. L->P;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388 P58012 UniProtKB Natural variant 108 108 . . . ID=VAR_062547;Note=In BPES%3B nuclear aggregation and cytoplasmic mislocalization%3B impaired transactivation activity. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=PMID:18484667 P58012 UniProtKB Natural variant 109 109 . . . ID=VAR_016886;Note=In BPES%3B type II%3B diffuse nuclear localization as wild type%3B impaired transactivation activity. N->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=PMID:12529855,PMID:18372316 P58012 UniProtKB Natural variant 134 134 . . . ID=VAR_062548;Note=In granulosa-cell tumors of the ovary%3B not commonly found in other tumor types. C->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:19516027,ECO:0000269|PubMed:19956657;Dbxref=dbSNP:rs1057519865,PMID:19516027,PMID:19956657 P58012 UniProtKB Natural variant 179 179 . . . ID=VAR_021201;Note=A->G;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12149404,ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs7432551,PMID:12149404,PMID:18484667 P58012 UniProtKB Natural variant 187 187 . . . ID=VAR_015181;Note=In POF3%3B does not affect nuclear localization%3B reduces transcriptional activation of OSR2. G->D;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12161610,ECO:0000269|PubMed:19429596;Dbxref=dbSNP:rs121908359,PMID:12161610,PMID:19429596 P58012 UniProtKB Natural variant 193 193 . . . ID=VAR_021202;Note=In BPES%3B type II. K->R;Dbxref=dbSNP:rs1057516162 P58012 UniProtKB Natural variant 215 215 . . . ID=VAR_021203;Note=In BPES. Y->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15257268,ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs1057516168,PMID:15257268,PMID:18484667 P58012 UniProtKB Natural variant 217 217 . . . ID=VAR_062549;Note=In BPES%3B diffuse nuclear localization%3B normal transcriptional activation. S->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=PMID:18484667 P58012 UniProtKB Natural variant 217 217 . . . ID=VAR_016887;Note=In BPES%3B diffuse nuclear localization%3B increased transactivation activity. S->F;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11468277,ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs797044527,PMID:11468277,PMID:12529855,PMID:18372316 P58012 UniProtKB Natural variant 234 234 . . . ID=VAR_037303;Note=In BPES%3B significant higher cytoplasmic retention compared to the wild-type protein. A->AAAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17089161;Dbxref=PMID:17089161 P58012 UniProtKB Natural variant 234 234 . . . ID=VAR_010782;Note=In BPES%3B type II. A->AAAAAAAAAAA;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11175783,ECO:0000269|PubMed:12400065;Dbxref=PMID:11175783,PMID:12400065 P58012 UniProtKB Natural variant 234 234 . . . ID=VAR_025306;Note=In BPES. A->AAAAAAAAAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.2 P58012 UniProtKB Natural variant 258 258 . . . ID=VAR_021204;Note=In POF3. Y->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12149404;Dbxref=dbSNP:rs28937885,PMID:12149404 P58012 UniProtKB Natural variant 285 285 . . . ID=VAR_015182;Note=P->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12161610;Dbxref=PMID:12161610 P58012 UniProtKB Natural variant 349 349 . . . ID=VAR_078138;Note=R->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27610946;Dbxref=dbSNP:rs201840174,PMID:27610946 P58012 UniProtKB Mutagenesis 25 25 . . . Note=Results in reduced sumoylation. Loss of transcriptional repression activity. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19744555;Dbxref=PMID:19744555 P58012 UniProtKB Helix 59 69 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Beta strand 70 75 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Helix 77 87 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Helix 89 92 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Helix 95 108 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Beta strand 112 115 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Beta strand 127 130 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU P58012 UniProtKB Helix 134 136 . . . Ontology_term=ECO:0007829;evidence=ECO:0007829|PDB:7VOU